Pubblicazioni

Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives  (2011)

Autori:
Dalla Pozza E; Donadelli M; Costanzo C; Zaniboni T; Dando I; Franchini M; Arpicco S; Scarpa A; Palmieri M
Titolo:
Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives
Anno:
2011
Tipologia prodotto:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Nazioni degli autori:
ITALIA
Lingua:
Inglese
Formato:
A Stampa
Referee:
Nome rivista:
Free Radical Biology and Medicine
ISSN Rivista:
0891-5849
N° Volume:
50
Numero o Fascicolo:
8
Intervallo pagine:
926-933
Codice PMID:
21236335
Parole chiave:
pancreatic adenocarcinoma, gemcitabine, zinc, dithiocarbamate, oxidative stress, apoptosis
Breve descrizione dei contenuti:
Pancreatic adenocarcinoma is a common malignancy that remains refractory to all available therapies, including the gold standard drug gemcitabine (GEM). We investigated the effect of the combination between GEM and the ionophore compounds pyrrolidine dithiocarbamate (PDTC) or disulfiram [DSF, 1-(diethylthiocarbamoyldisulfanyl)-N,N-diethyl-methanethioamide] on p53(-/-) pancreatic adenocarcinoma cell growth. PDTC or DSF synergistically inhibited cell proliferation when used in combination with GEM by inducing apoptotic cell death. This effect was associated to an increased mitochondrial O(2)(.-) production and was further enhanced by zinc ions. Basal levels of mitochondrial O(2)(.-) or manganese superoxide dismutase (MnSOD) strictly correlated with the IC(50) for GEM or the percentage of synergism. Thus, the most relevant values of the antiproliferative synergism were obtained in GEM-resistant pancreatic adenocarcinoma cell lines. Interestingly, the GEM-sensitive T3M4 cells transfected with MnSOD expression vector showed mitochondrial O(2)(.-) and IC(50) for GEM similar to those of resistant cell lines. In vivo experiments performed on nude mice xenotransplanted with the GEM-resistant PaCa44 cell line showed that only the combined treatment with GEM and DSF/Zn completely inhibited the growth of the tumoral masses. These results and the consideration that DSF is already used in clinics strongly support GEM and DSF/Zn combination as a new approach to overcome pancreatic cancer resistance to standard chemotherapy.
Pagina Web:
http://preview.ncbi.nlm.nih.gov/pubmed/21236335
Id prodotto:
58831
Handle IRIS:
11562/347594
depositato il:
29 febbraio 2012
ultima modifica:
23 novembre 2016
Citazione bibliografica:
Dalla Pozza E; Donadelli M; Costanzo C; Zaniboni T; Dando I; Franchini M; Arpicco S; Scarpa A; Palmieri M, Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives «Free Radical Biology and Medicine» , vol. 50 , n. 82011pp. 926-933

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

Progetti Collegati
Titolo Dipartimento Responsabili
<<indietro

Attività

Strutture